MANAGEMENT OF THE PSEUDOBULBAR AFFECT (PBA) IN KABUKI SYNDROME COMBINED DEXTROMETHORPHAN-FLUOXETINE TREATMENT AS AN ALTERNATIVE TO DEXTROMETHORPHAN/QUINIDINE

Authors

  • Victor Hugo Cordova Pharmacy School UFRGS
  • André Goldani
  • Paulo Belmonte-de-Abreu Medicine School UFRGS

Keywords:

Neurology, genetic syndrome, off label medicine, behavior

Abstract

A case report of a patient with pseudo bulbar affect previous treatments included haloperidol (10mg), Inosina pranobex (600mg), clozapine (600mg), olanzapine (20mg), carbamazepine (200mg), paroxetine (20mg), phenobarbital (100mg) and topiramate (50mg), all suspended at August 2016, with current use of quetiapine (700mg) Chlorpromazine (600mg) (+ 200mg on demand of aggression), clonazepam (4 mg), valproate 2500 mg, propranolol (40mg). that was successful treated with off label treatment (dextromethorphan plus quinidine). Previous Brief Psychiatric Rating Scale and Clinical Global ImpressionImprovement was applied after and before treatment with dextromethorphan (20mg) plus fluoxetine (20 mg, further increased to 40 mg). Previous Brief Psychiatric Rating Scale BPRS score 56 points and Clinical Global Impression-Severity (CGI-S) Score was 6 (severely ill). The addition of dextromethorphan (20mg) and fluoxetine (20 mg, further increased to 40 mg), allowed clear improvement of pathological crying and outbursts, with BPRS decrease of 8 points and Clinical Global Impression-Improvement (CGI-I) 2 (much improved) – especially pertaining to PBA related symptoms and aggressive behavior. There were no noticeable side-effects. This case report shown an interesting clinical response. It’s could be a great alternative in treatment of pseudobulbar affect symptoms. Even though an only case and a great clinical study be necessary.

Downloads

Download data is not yet available.

Downloads

Published

2021-03-11

How to Cite

1.
Cordova VH, Goldani A, Belmonte-de-Abreu P. MANAGEMENT OF THE PSEUDOBULBAR AFFECT (PBA) IN KABUKI SYNDROME COMBINED DEXTROMETHORPHAN-FLUOXETINE TREATMENT AS AN ALTERNATIVE TO DEXTROMETHORPHAN/QUINIDINE. Clin Biomed Res [Internet]. 2021Mar.11 [cited 2022May22];40(3). Available from: https://www.seer.ufrgs.br/index.php/hcpa/article/view/101171

Issue

Vol. 40 No. 3 (2020)

Section

Case Report

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).